Esophageal dysmotility in scleroderma patients with different disease forms and ANA patterns: A scintigraphic study in 100 cases;Alterazioni della peristalsi esofagea nelle diverse forme cliniche e specificita' anticorpali della sclerodermia: Studio scintigrafico in 100 pazienti

Reumatismo

Volumn 55, Issue 2, 2003, Pages 86-92

  Cozzi, Franco ^a,b   Zucchetta, P ^b   Durigon, N ^a   Marzola, M C ^b   Bullo, A ^a   Favaro, M ^a   Bui, F ^b   Todesco, S ^a  

^a UNIVERSITY OF PADOVA   (Italy)

^b UNIVERSITY HOSPITAL OF PADOVA   (Italy)

Author keywords

Esophageal dysmotility; Scintigraphy; Systemic sclerosis

Indexed keywords

ANTINUCLEAR ANTIBODY; CENTROMERE ANTIBODY; TECHNETIUM 99M;

ADULT; AGED; ARTICLE; DISEASE SEVERITY; ESOPHAGUS FUNCTION DISORDER; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PREVALENCE; SCINTIGRAPHY; SCLERODERMA; SYSTEMIC SCLEROSIS;

ADULT; AGED; ANALYSIS OF VARIANCE; ANTIBODIES, ANTINUCLEAR; ANTIBODY SPECIFICITY; CHI-SQUARE DISTRIBUTION; ESOPHAGEAL MOTILITY DISORDERS; ESOPHAGUS; FEMALE; HUMANS; MALE; MIDDLE AGED; SCLERODERMA, SYSTEMIC;

EID: 0038005554     PISSN: 00487449     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Rocco VK, Hurd ER. Scleroderma and sclerodermalike disorders. Semin Arthritis Rheum 1986; 16: 22-69.
2. Ferri C, Valentini G, Cozzi F, Sebastiani M, Michelassi C, La Montagna G, et al. Systemic sclerosis: demographic, clinical, and serologic features and survival in 1012 Italian patients. Medicine (Baltimore) 2002; 81: 139-53.
3. D'Angelo WA, Fries JF, Masi AT, Shulman LE. Pathologic observations in systemic sclerosis (scleroderma). A study of fifty-eight autopsy cases and fifty-eight matched controls. Am J Med 1969; 46: 428-40.
4. Russel ML, Friesen D, Henderson RD, Hanna WM. Ultrastructure of the esophagus in scleroderma. Arthritis Rheum 1982; 25: 1117-23.
5. LeRoy EC, Trojanowska M, Smith EA. The pathogenesis of scleroderma (systemic sclerosis, SSc). Clin Exp Rheumatol 1991; 9: 173-7.
6. Dessein PH, Joffe BI, Metz RM, Millar DL, Lawson M, Stanwix AE. Autonomic dysfunction in systemic sclerosis: sympathetic overactivity and instability. Am J Med 1992; 93: 143-50.
7. Kahaleh B, Matucci-Cerinic M. Raynaud's phenomenon and scleroderma. Dysregulated neuroendothelial control of vascular tone. Arthritis Rheum 1995; 38: 1-4.
8. Strelhow D, Korn JH. Biology of the scleroderma fibroblast. Curr Opin Rheumatol 1998; 10: 572-8.
9. Murphy JR, McNally P, Peller P, Shay SS. Prolonged clearance is the primary abnormal reflux parameter in patients with progressive systemic sclerosis and esophagitis. Dig Dis Sci 1992; 37: 833-41.
10. Wegener M, Adamek RJ, Wedmann B, Jergas M, Altmeyer P. Gastrointestinal transit through esophagus, stomach, small and large intestine in patients with progressive systemic sclerosis. Dig Dis Sci 1994; 39: 2209-15.
11. Sjogren RW. Gastrointestinal motility disorders in scleroderma. Arthritis Rheum 1994; 37: 1265-82.
12. Weston S, Thumshirn M, Wiste J, Camilleri M. Clinical and upper gastrointestinal motility features in systemic sclerosis and related disorders. Am J Gastroenterol 1998; 93: 1085-9.
13. Rose S, Young MA, Reynolds JC. Gastrointestinal manifestations of scleroderma. Gastroenterol Clin North Am 1998; 27: 563-94.
14. Kaye SA, Siraj QH, Agnew J, Hilson A, Black CM. Detection of early asymptomatic esophageal dysfunction in systemic sclerosis using a new scintigraphic grading method. J Rheumatol 1996; 23: 297-301.
15. Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980; 23: 581-90.
16. Giordano M, Valentini G, Migliaresi S, Picillo U, Vatti M. Different antibody patterns and different prognoses in patients with scleroderma with various extent of skin sclerosis. J Rheumatol 1986; 13: 911-6.
17. Siraj QH, Buscombe JR, Kaye SA, Agnew JE, Black CM, Hilson AJW. Esophageal scintigraphy in systemic sclerosis: a simplified imaging and reporting method. J Nucl Med Technol 1996; 24: 316-320.
18. Klein HA, Wald A, Graham TO, Campbell WL, Steen VD. Comparative studies of esophageal function in systemic sclerosis. Gastroenterology 1992; 102: 1551-6.
19. Parkman HP, Maurer AH, Caroline DF, Miller DL, Krevsky B, Fisher RS. Optimal evaluation of patients with nonobstructive esophageal dysphagia. Manometry, scintigraphy, or videoesophagography? Dig Dis Sci 1996; 41: 1355-68.
20. Cozzi F, Chiesura Corona M, Rizzi M, Durigon N, Mancin S, Todesco S. La TC polmonare ad alta risoluzione nelle diverse forme cliniche e specificità anticorpali della sclerodermia. Reumatismo 2001; 53: 55-62.
21. Marie I, Dominique S, Levesque H, Ducrotte P, Denis P, Hellot MF, et al. Esophageal involvement and pulmonary manifestations in systemic sclerosis. Arthritis Rheum 2001; 45: 346-54.
22. Edenbrandt L, Theander E, Hogstrom M, Scheja A, Akesson A, Palmer J. Esophageal scintigraphy of systemic sclerosis. J Nucl Med 1995; 36: 1533-8.
23. Bassotti G, Battaglia E, Debernardi V, Germani U, Quiriconi F, Dughera L, et al. Esophageal dysfunction in scleroderma: relationship with disease subsets. Arthritis Rheum 1997; 40: 2252-9.
24. Villadsen GE, Storkholm J, Zachariae H, Hendel L, Bendtsen F, Gregersen H. Oesophageal pressure-crosssectional area distributions and secondary peristalsis in relation to subclassification of systemic sclerosis. Neurogastroenterol Motil 2001; 13: 199-210.
25. Akesson A, Wollheim FA. Organ manifestation in 100 patients with progressive systemic sclerosis: a comparison between the CREST syndrome and diffuse scleroderma. Br J Rheumatol 1989; 28: 281-6.
26. Kinuya K, Nakajima K, Kinuya S, Michigishi T, Tonami N, Takehara K. Esophageal hypomotility in systemic sclerosis: close relationship with pulmonary involvement. Ann Nucl Med 2001; 15: 97-101.
27. Stacher G, Merio R, Budka C, Schneider C, Smolen J, Tappeiner G. Cardiovascular autonomic function, autoantibodies, and esophageal motor activity in patients with systemic sclerosis and mixed connective tissue disease. J Rheumatol 2000; 27: 692-7.
28. Dick T, Mierau R, Bartz-Bazzanella P, Alavi M, Stoyanova-Scholz M, Kindler J, et al. Coexistence of antitopoisomerase I and anticentromere antibodies in patients with systemic sclerosis. Ann Rheum Dis 2002; 61: 121-7.
29. Steen VD, Powell DL, Medsger TA Jr. Clinical correlations and prognosis based on serum autoantibodies in patients with systemic sclerosis. Arthritis Rheum 1988; 31: 196-203.
30. Kuwana M, Kaburaki J, Okano Y, Tojo T, Homma M. Clinical and prognostic associations based on serum antinuclear antibodies in Japanese patients with systemic sclerosis. Arthritis Rheum 1994; 37: 75-83.
31. Diot E, Giraudeau B, Diot P, Degenne D, Ritz L, Guilmot JL, et al. Is anti-topoisomerasi I a serum marker of pulmonary involvement in systemic sclerosis? Chest 1999; 11: 715-20.
32. Weiner ES, Earnshaw WC, Senecal JL, Bordwell B, Johnson P, Rothfield NF. Clinical associations of anticentromere antibodies and antibodies to topoisomerase I. A study of 355 patients. Arthritis Rheum 1988; 31: 378-85.